AYŞENUR PAÇ KISAARSLAN
(Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Romatoloji Anabilim Dalı, Kayseri, Türkiye)
Betül SÖZERİ
(Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Romatoloji Anabilim Dalı, Kayseri, Türkiye)
Zübeyde GÜNDÜZ
(Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Romatoloji Anabilim Dalı, Kayseri, Türkiye)
Gökmen ZARARSIZ
(Erciyes Üniversitesi, Tıp Fakültesi, Biyoistatistik Anabilim Dalı, Kayseri, Türkiye)
Hakan PORAZOĞLU
(Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Romatoloji Anabilim Dalı, Kayseri, Türkiye)
Ruhan DÜŞÜNSEL
(Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Romatoloji Anabilim Dalı, Kayseri, Türkiye)
Yıl: 2019Cilt: 6Sayı: 3ISSN: 2147-9720 / 2148-4279Sayfa Aralığı: 130 - 135İngilizce

45 0
Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis
Objective: Treatments for enthesitis-related arthritis (ERA) consist of a mono- or combination therapy with non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs (DMARDs), and biological agents, and they are primarily based on adult studies and studies on other forms of juvenile idiopathic arthritis, depending on whether there is axial or peripheral involvement. We use DMARDs frequently in our daily practice, even in patients with axial involvement. The main reason for this is that the health insurance system in Turkey does not allow the use of Tumor Negrosis Factor (TNF) blockers as the first line of treatment. The aim of this study is to evaluate the factors affecting the duration of DMARDs application in patients with ERA. Methods: Fifty-two patients with ERA were accepted in this retrospective cohort study. These patients did not have an inflammatory bowel disease, reactive arthritis or undifferentiated arthritis, psoriasis, and familial Mediterranean fever. Demographic characteristics, medical history, the initial and follow-up physical examination, initial Juvenile Spondyloarthritis Disease Activity Index (JSpADA), initial laboratory tests, radiographic tests, Juvenile Arthritis Damage Index-articulary (JADI-A) and extra-articulary (JADI-E) on the last admission, and data on medical treatments were recorded from the registered data. The univariate Cox proportional hazards regression analyses was used to determine factors affecting the non-response time of ERA patients to DMARDs before the biological treatment was started. Results: Twenty-seven patients (52%) achieved remission with DMARDs, while 25 (48%) patients did not. The age at diagnosis (HR=1.12; p=0.247); gender (HR=2.53; p=0.210); family history of ankylosing spondylitis (HR=1.17; p=0.730); inflammatory back pain (HR=0.57; p=0.175); the shoulder (HR=0.75 p=0.706), hip (HR=0.45; p=0.129), and small-joint involvement (HR=1.53; p=0.439); sacroiliitis with physical examination (HR=0.90; p=0.814) and magnetic resonance imaging (MRI) (HR=2.84; p=0.110); enthesitis (HR=0.83; p=0.670); presence of uveitis (HR=2.04; p=0.342); presence of HLA-B27 (HR=1.39; p=0.524); initial high acute phase reactants levels(HR=1.89; p=0.183); initial JSpADA score (HR=0.98; p=0.944); and last JADI-A (HR=1.41; p=0.060) score did not affect the duration of DMARDs treatment before switching to biological treatments. Conclusion: In our study, the absence of factors affecting the duration of DMARDs application in patients with ERA showed that DMARDs may still be applied as the first line of treatment.
DergiAraştırma MakalesiErişime Açık
  • 1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
  • 2. Fujikawa S, Okuni M. A nation wide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn 1997; 39: 242-4. [CrossRef]
  • 3. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–1993. Is the epidemiology changing? Arthritis Rheum 1996; 39: 1385-90. [CrossRef]
  • 4. Mielants H, Veys EM, Maertens M, Goemaere S, De Clercq L, Castro S, et al. Prevalence of inflammatoryrheumaticdiseases in an adolescent urban studentpopulation, age 12 to 18, in Belgium. Clin Exp Rheumatol 1993; 11: 563-7.
  • 5. Ozen S, Karaaslan Y, Ozdemir O, Saatci U, Bakkaloglu A, Koroglu E, et al. Prevelance of Juvenil chronic arthrtis and Familial Mediterranean fever in Turkey: a field study. J Rheumatol 1998; 25: 2445-9.
  • 6. Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Pediatric Rheumatology association. Clin Exp Rheum 2011; 29: 111-6.
  • 7. Weiss PF. Diagnosis and treatment of enthesitis-related arthritis. Adolesc Health Med Ther 2012: 3 67-74. [CrossRef]
  • 8. Weiss PF. Evaluation and Treatment of Enthesitis-Related Arthritis. Curr Med Lit Rheumatol 2013; 32: 33-41.
  • 9. Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis-relatedarthritis is associated with higher pain in tensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2012; 39: 2341-51. [CrossRef]
  • 10. Ramanathan A, Srinivasalu H, Colbert RA. Update on juvenile spondyloarthritis. Rheum Dis Clin North Am 2013; 39: 767-88. [CrossRef]
  • 11. Gmuca S, Weiss PF. Evaluation andtreatment of childhood enthesitis-related arthritis. Curr Treatm Opt Rheumatol 2015; 1: 350-64. [CrossRef]
  • 12. Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, Hernández-Garduño A, Goycochea-Robles MV. A 26 weekrandomised, doubleblind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61: 941-2. [CrossRef]
  • 13. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, De Witt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-82. [CrossRef]
  • 14. Weiss PF, Maksymowych WP, Lambert RG, Jaremko JL, Biko DM, Paschke J, et al. Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Structural Score in Children. J Rheumatol 2018; 45: 1411-7. [CrossRef]
  • 15. Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, De Witt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken) 2014; 66: 1775-82. [CrossRef]
  • 16. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 2092-102. [CrossRef]
  • 17. Flatø B, Hoffmann-Vold AM, Reiff A, Førre Ø, Lien G, Vinje O. Long-termoutcomeandprognosticfactors in enthesitis-relatedarthritis: a casecontrolstudy. Arthritis Rheum 2006; 54: 3573-82. [CrossRef]
  • 18. Weiss PF, Beukelman T, SchanbergLE, SchanbergLE, Kimura Y, Colbert RA. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis specific pain across juvenile arthritis (JIA) categories: preliminary analyses from the CARRAnetregistry. Arthritis Rheum 2011; 63(10 Suppl): 280.
  • 19. Adrovic A, Barut K, Sahin S, Kasapcopur O. Juvenile Spondyloarthropathies. Curr Rheumatol Rep 2016; 18: 55. [CrossRef]
  • 20. Flatø B, Smerdel A, Johnston V, Lien G, Dale K, Vinje O, et al. The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 986-94. [CrossRef]
  • 21. Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 2010; 37: 2402-8. [CrossRef]
  • 22. Berntson L, Nordal E, Aalto K, Peltoniemi S, Herlin T, Zak M, et al. HLA-B27 predicts a more chronic disease course in an 8-year follow up cohort of patients with juvenile idiopathic arthritis. J Rheumatol 2013; 40: 725-31. [CrossRef]
  • 23. Goirand M, Breton S, Chevallier F, Duong NP, Uettwiller F, Melki I, et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol Online J 2018; 16: 21. [CrossRef]
  • 24. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis-data from Dutch arthritis and biologicals in children register,1999-2010. J Rheumatol 2011; 38: 2258-63. [CrossRef]
  • 25. Hugle B, Burgos-Vargas R, Inman RD, O'Shea F, Laxer RM, Stimec J, et al. Long term outcome of anti-tumornecrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 2014; 32: 424-31.
  • 26. Barut K, Adrovic A, Şahin S, Kasapçopur O. Juvenile Idiopathic Arthritis. Balkan Med J 2017; 34: 90-101. [CrossRef]
  • 27. Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis 2013; 5: 45-54. [CrossRef]
  • 28. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of subcutaneousmethotrexate in activeankylosingspondylitis: a 16-week open -labeltrial. Ann Rheum Dis 2007; 66: 419-21. [CrossRef]
  • 29. Dougados M, Baeten D. Spondyloarthritis Lancet 2011; 377: 2127-37. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.